National Renal Programme 2012 [presentation]

Le résumé fourni par la source

Strategic Vision for ESKD Services (National Renal Strategy Review; NSP11; NSP12)• The number of patients with ESKD will increase by 40-50 p.m.p. patients) per annum.• Transplantation is the best therapy for suitable patients and represents the best value for money.• Home therapies offer an enhanced quality therapy and represent the next best value for money.• Hospital/Clinic-based haemodialysis can also be an excellent therapy but is • Hospital/Clinic-based haemodialysis can also be an excellent therapy but is associated with the highest social costs, consumable costs, overhead costs, transport costs and ancillary costs.• Planning should aim to maximise the proportion of patients receiving the best value therapies.• HSE Area-based planning will optimise regional Capacity, Configuration and Governance of services.• System-wide streamlining of Procurement, Contracting and Funding will enhance this.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.